Reason for request

Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the ‘Central neuropathic pain in adults’ indication extension.

Clinical Benefit

Substantial

The actual benefit of LYRICA in the treatment of central neuropathic pain in adults is substantial.


Clinical Added Value

no clinical added value

Lyrica does not provide any improvement in actual benefit (IAB level V) over the usual management of central neuropathic pain in adults.


Contact Us

Évaluation des médicaments